普崙司特市場規模、佔有率和成長分析：按劑量效力、劑型、患者群體、治療應用、分銷管道和地區分類 - 行業預測，2026-2033 年

2024 年全球普崙司特市場價值為 17 億美元，預計到 2033 年將從 2025 年的 17.7 億美元成長至 24.6 億美元，預測期（2026-2033 年）的複合年成長率為 4.2%。

全球普崙司特市場主要受慢性呼吸系統疾病和過敏性疾病日益普遍的推動，促使口服白三烯受體拮抗劑在門診治療中得到應用。該市場涵蓋品牌藥和非專利普崙司特產品，並受益於口服治療，從而提高了患者的依從性，尤其是在吸入器使用困難的情況下。由於價格更低、醫保覆蓋範圍更廣以及醫療服務提供者接受度更高，非專利藥的普及擴大了藥物的可及性，尤其是在門診治療中，兒童和老年人等患者群體受益匪淺。此外，人工智慧正在革新研發和商業化流程，透過簡化化合物選擇、降低風險、透過新的給藥方法提高患者依從性、最佳化市場細分以及在日益激烈的非專利競爭中最佳化產品部署，從而推動市場成長。

全球普崙司特市場的成長要素

氣喘及相關過敏性呼吸系統疾病的日益普遍，使得更多患者能夠從普崙司特等靶向白三烯受體拮抗劑中獲益，從而促使人們對該治療領域投入更多資金和關注。當傳統治療方法無法有效控制病情時，醫療專業人員會積極尋求替代療法，這使得人們對作用機制多樣的藥物產生了濃厚的興趣。這種不斷成長的臨床需求推動了研究活動，促進了市場准入，並提高了醫療專業人員的認知度，所有這些因素共同促成了全球市場對普崙司特相關產品需求的顯著成長和持續攀升。

全球普崙司特市場的限制因素

由於副作用報告和對其長期安全性的擔憂，全球普崙司特市場面臨挑戰。這些問題導致處方醫生持謹慎態度，他們往往更傾向於選擇廣為人知、廣為接受且成熟的治療方法。安全性考量在臨床決策中起著至關重要的作用，通常需要加強監測和風險管理策略，這可能會限制某些病患小組群體對該藥物的使用。醫護人員和患者的這種謹慎態度正在減緩處方趨勢和市場滲透率。此外，這也促使生產商加強對安全性研究和教育計畫的投入，以促進普崙司特的更廣泛應用。

全球普崙司特市場趨勢

全球普崙司特市場正經歷著向精準醫療的顯著轉變，這主要得益於藥物基因體學和生物標記相關策略的推動，這些策略能夠根據個別患者的特徵最佳化治療方法。診斷工具和數位化用藥依從性項目的整合，使醫療專業人員能夠識別出最能從白三烯受體拮抗劑中獲益的患者，從而最佳化劑量並監測療效。製藥公司與診斷設備製造商之間的合作正在推動產品標籤的完善，並支持精準行銷。這種個人化方法不僅增強了人們對臨床結果和醫生處方的信心，還創造了獨特的價值提案，有助於在特定細分市場進行策略性定價和合約執行。

目錄

介紹

• 調查目的
• 市場定義和範圍

調查方法

• 研究過程
• 二級資料和一級資料的方法
• 市場規模估算方法

執行摘要

• 全球市場展望
• 市場主要亮點
• 細分市場概覽
• 競爭環境概述

市場動態及展望

• 總體經濟指標
• 促進者和機會
• 抑制因素和挑戰
• 供給面趨勢
• 需求面趨勢
• 波特的分析和影響

關鍵市場分析

• 關鍵成功因素
• 影響市場的因素
• 主要投資機會
• 生態系測繪
• 2025年市場魅力指數
• PESTLE分析
• 監理情勢
• 價格分析
• 專利分析

全球普崙司特市場規模：依效力分類

• 75 mg
• 150 mg
• 300 mg

全球普崙司特市場規模：以劑型分類

• 藥片
• 吸入器
• 其他

全球普崙司特市場規模：依患者群體分類

• 兒童
• 成人
• 老年人

全球普崙司特市場規模：依治療應用分類

• 氣喘
• 慢性阻塞性肺病（COPD）

全球普崙司特市場規模：依分銷管道分類

• 醫院藥房
• 零售藥房
• 網路藥房

全球普崙司特市場規模：依地區分類

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲國家
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 其他亞太國家
• 拉丁美洲
  • 墨西哥
  • 巴西
  • 其他拉丁美洲國家
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲國家

競爭資訊

• 前五大公司對比
• 主要企業2025年的市場定位
• 主要市場公司採取的策略
• 近期市場趨勢
• 企業市場占有率分析，2025 年
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 按細分市場進行企業市佔率分析
  • 銷售收入年比比較（2023-2025 年）

主要企業簡介

• Mylan
• Teva Pharmaceuticals
• Cipla
• Sun Pharmaceutical Industries
• Aurobindo Pharma
• Hikma Pharmaceuticals
• Sandoz
• Zydus Cadila
• Amgen
• GSK
• Roche
• AbbVie
• Pfizer
• Merck & Co.
• Johnson & Johnson
• Novartis
• Sanofi
• Bayer
• Eli Lilly
• Boehringer Ingelheim

結論與建議

Global Pranlukast Market size was valued at USD 1.7 Billion in 2024 and is poised to grow from USD 1.77 Billion in 2025 to USD 2.46 Billion by 2033, growing at a CAGR of 4.2% during the forecast period (2026-2033).

The global pranlukast market is significantly driven by the increasing prevalence of chronic respiratory and allergic conditions, which promote the use of oral leukotriene receptor antagonists for outpatient care. This market encompasses both branded and generic forms of pranlukast, particularly benefitting from oral therapies that enhance patient adherence, especially when inhalers are challenging to use. The shift toward generic offerings is expanding access as lower prices increase payer coverage and provider acceptance, especially in outpatient settings catering to populations such as children and the elderly. Furthermore, AI is revolutionizing R&D and commercialization by streamlining compound selection, reducing risks, enhancing patient adherence through novel delivery methods, refining market segmentation, and optimizing rollouts amidst rising generic competition, thereby propelling market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Pranlukast market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Pranlukast Market Segments Analysis

Global pranlukast market is segmented by dosage strength, formulation, patient demographics, therapeutic use, distribution channel and region. Based on dosage strength, the market is segmented into 75 MG, 150 MG and 300 MG. Based on formulation, the market is segmented into Tablets, Inhalers and Others. Based on patient demographics, the market is segmented into Pediatric, Adult and Geriatric. Based on therapeutic use, the market is segmented into Asthma and Chronic Obstructive Pulmonary Disease (COPD). Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Pranlukast Market

The increasing prevalence of asthma and associated allergic respiratory conditions has broadened the patient base that stands to gain from targeted leukotriene receptor antagonists like pranlukast, driving investment and attention in this therapeutic area. Medical professionals are actively seeking alternatives when traditional treatments do not achieve adequate control, leading to a heightened interest in medications with varied mechanisms of action. This escalating clinical requirement fuels research initiatives, aids in market entry efforts, and enhances awareness among healthcare providers, all of which contribute to a significant surge in demand and ongoing growth for pranlukast-related products within the global market.

Restraints in the Global Pranlukast Market

The global pranlukast market faces challenges due to reports of adverse reactions and concerns regarding long-term safety profiles. These issues lead to a degree of caution among prescribers who may prefer established therapies that are well-known and widely accepted. Safety considerations play a significant role in clinical decision-making, often requiring enhanced monitoring or risk management strategies that can limit the drug's adoption within specific patient groups. This cautious approach from both healthcare providers and patients consequently slows down the prescribing momentum and market penetration. Additionally, it drives manufacturers to invest in further safety studies and educational programs to foster broader acceptance of pranlukast.

Market Trends of the Global Pranlukast Market

The global Pranlukast market is witnessing a significant trend towards precision medicine, driven by pharmacogenomic and biomarker-related strategies that tailor therapies to individual patient profiles. The integration of diagnostic tools and digital adherence programs empowers healthcare providers to pinpoint patients who will most benefit from leukotriene receptor antagonism, facilitating optimized dosing and response monitoring. Collaborations between pharmaceutical companies and diagnostics firms enhance the refining of product labels and support targeted marketing efforts. This personalized approach not only boosts clinical outcomes and prescribing confidence among physicians but also creates unique value propositions that contribute to strategic pricing and contracting in specialized market segments.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape
• Pricing Analysis
• Patent Analysis

Global Pranlukast Market Size by Dosage Strength & CAGR (2026-2033)

• Market Overview
• 75 MG
• 150 MG
• 300 MG

Global Pranlukast Market Size by Formulation & CAGR (2026-2033)

• Market Overview
• Tablets
• Inhalers
• Others

Global Pranlukast Market Size by Patient Demographics & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Pranlukast Market Size by Therapeutic Use & CAGR (2026-2033)

• Market Overview
• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

Global Pranlukast Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Pranlukast Market Size & CAGR (2026-2033)

• North America (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
  • US
  • Canada
• Europe (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Dosage Strength, Formulation, Patient Demographics, Therapeutic Use, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Mylan
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aurobindo Pharma
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sandoz
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zydus Cadila
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations